tradingkey.logo
tradingkey.logo
Suchen

Sight Sciences Inc

SGHT
Zur Watchlist hinzufügen
5.450USD
+0.010+0.18%
Handelsschluss 07/02, 13:00ETKurse um 15 Minuten verzögert
291.54MMarktkapitalisierung
VerlustKGV TTM

mehr Informationen über Sight Sciences Inc Unternehmen

Sight Sciences, Inc. is an eyecare technology company. The Company is focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. The Company operates through two segments: Surgical Glaucoma and Dry Eye. The product portfolio for the Surgical Glaucoma segment features the OMNI Surgical System, which is an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma, and the SION Surgical Instrument is a bladeless, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork. The product portfolio for the Dry Eye segment consists of the TearCare System (TearCare) for ophthalmologists and optometrists. TearCare is used by adult patients with evaporative dry eye disease due to meibomian gland disease (MGD), enabling clearance of gland obstructions by physicians to address the cause of dry eye disease.

Sight Sciences Inc Informationen

BörsenkürzelSGHT
Name des UnternehmensSight Sciences Inc
IPO-datumJul 15, 2021
CEOBadawi (Paul)
Anzahl der mitarbeiter216
WertpapierartOrdinary Share
GeschäftsjahresendeJul 15
Addresse4040 Campbell Ave,
StadtMENLO PARK
BörseNASDAQ OMX - NASDAQ BASIC
LandUnited States of America
Postleitzahl94025
Telefon14158890550
Websitehttps://www.sightsciences.com/
BörsenkürzelSGHT
IPO-datumJul 15, 2021
CEOBadawi (Paul)

Führungskräfte von Sight Sciences Inc

Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Paul Badawi
Mr. Paul Badawi
President, Chief Executive Officer, Co-Founder, Director
President, Chief Executive Officer, Co-Founder, Director
5.54M
+3.64%
Mr. Staffan Encrantz
Mr. Staffan Encrantz
Independent Chairman of the Board
Independent Chairman of the Board
2.07M
+2.05%
Dr. David Badawi, M.D.
Dr. David Badawi, M.D.
Co-Founder, Chief Technology Officer, Director
Co-Founder, Chief Technology Officer, Director
1.80M
+2.22%
Ms. Alison Bauerlein
Ms. Alison Bauerlein
Chief Operating Officer, Principal Operating Officer
Chief Operating Officer, Principal Operating Officer
169.81K
-7.50%
Mr. Donald J. Zurbay, CPA
Mr. Donald J. Zurbay, CPA
Independent Director
Independent Director
103.61K
+27.28%
Ms. Catherine Mazzacco
Ms. Catherine Mazzacco
Independent Director
Independent Director
96.70K
+29.22%
Mr. Jeremy Bragg Hayden, J.D.
Mr. Jeremy Bragg Hayden, J.D.
Chief Legal Officer
Chief Legal Officer
87.27K
-40.39%
Mr. Gerhard F. (Gary) Burbach
Mr. Gerhard F. (Gary) Burbach
Independent Director
Independent Director
73.18K
+38.62%
Dr. Tamara R. Fountain, M.D.
Dr. Tamara R. Fountain, M.D.
Independent Director
Independent Director
--
--
Mr. Jim Rodberg
Mr. Jim Rodberg
Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer, Treasurer
Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer, Treasurer
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Paul Badawi
Mr. Paul Badawi
President, Chief Executive Officer, Co-Founder, Director
President, Chief Executive Officer, Co-Founder, Director
5.54M
+3.64%
Mr. Staffan Encrantz
Mr. Staffan Encrantz
Independent Chairman of the Board
Independent Chairman of the Board
2.07M
+2.05%
Dr. David Badawi, M.D.
Dr. David Badawi, M.D.
Co-Founder, Chief Technology Officer, Director
Co-Founder, Chief Technology Officer, Director
1.80M
+2.22%
Ms. Alison Bauerlein
Ms. Alison Bauerlein
Chief Operating Officer, Principal Operating Officer
Chief Operating Officer, Principal Operating Officer
169.81K
-7.50%
Mr. Donald J. Zurbay, CPA
Mr. Donald J. Zurbay, CPA
Independent Director
Independent Director
103.61K
+27.28%
Ms. Catherine Mazzacco
Ms. Catherine Mazzacco
Independent Director
Independent Director
96.70K
+29.22%

Häufig gestellte Fragen

Wer sind die fünf größten Anteilseigner von Sight Sciences Inc?

Die fünf größten Anteilseigner von Sight Sciences Inc sind: Mr. Paul Badawi

Wie viele Institutionen halten Anteile an Sight Sciences Inc (SGHT)?

Mit Stand vom 2026Q1 halten 200 Institutionen Anteile an Sight Sciences Inc, mit einem Gesamtmarktwert von etwa 27.85M, was 51.74% der Gesamtanteile entspricht. Im Vergleich zum 2025Q4 ist der institutionelle Aktienbesitz um 944720.00 gestiegen.